RG
Redmile Group Portfolio holdings
AUM
$940M
This Quarter Return
+49.07%
1 Year Return
+75.78%
3 Year Return
+543.67%
5 Year Return
+585.96%
10 Year Return
+6,653.82%
AUM
$1.43B
AUM Growth
+$1.43B
(-15%)
Cap. Flow
-$148M
Cap. Flow
% of AUM
-10.33%
Top 10 Holdings %
Top 10 Hldgs %
54.7%
Holding
66
New
3
Increased
9
Reduced
40
Closed
4
Top Buys
| 1 |
CBLL
CeriBell, Inc. Common Stock
CBLL
|
$11.3M |
| 2 |
RAPT Therapeutics
RAPT
|
$9.43M |
| 3 |
Neurogene
NGNE
|
$8.12M |
| 4 |
LivaNova
LIVN
|
$7.8M |
| 5 |
89bio
ETNB
|
$4.67M |
Top Sells
| 1 |
AUGX
Augmedix, Inc. Common Stock
AUGX
|
$38.5M |
| 2 |
CTLT
CATALENT, INC.
CTLT
|
$36.1M |
| 3 |
Scholar Rock
SRRK
|
$29.8M |
| 4 |
Kymera Therapeutics
KYMR
|
$11.8M |
| 5 |
Amicus Therapeutics
FOLD
|
$11.2M |
Sector Composition
| 1 | Healthcare | 100% |
| 2 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Scholar Rock
SRRK
$3.14B
| $197M | 13.7% | 4,549,881 -688,956 | -13% | -$29.8M |
|
2
Krystal Biotech
KRYS
$4.27B
| $118M | 8.22% | 753,175 -57,070 | -7% | -$8.94M |
|
3
Nurix Therapeutics
NRIX
$714M
| $79M | 5.51% | 4,192,627 -88,354 | -2% | -$1.66M |
|
4
Zymeworks
ZYME
$1.12B
| $70.9M | 4.94% | 4,840,463 -261,448 | -5% | -$3.83M |
|
|
5
Amicus Therapeutics
FOLD
$2.34B
| $66.5M | 4.63% | 7,054,890 -1,191,702 | -14% | -$11.2M |
|
6
Replimune Group
REPL
$422M
| $59.4M | 4.14% | 4,905,527 +124,344 | +3% | +$1.51M |
|
7
Immunome
IMNM
$828M
| $51.3M | 3.57% | 4,828,026 -61,528 | -1% | -$653K |
|
8
Stoke Therapeutics
STOK
$1.08B
| $50.7M | 3.53% | 4,593,629 -119,880 | -3% | -$1.32M |
|
|
9
LivaNova
LIVN
$3.08B
| $48.3M | 3.37% | 1,043,539 +168,500 | +19% | +$7.8M |
|
|
10
Kymera Therapeutics
KYMR
$2.95B
| $44.3M | 3.09% | 1,100,432 -292,824 | -21% | -$11.8M |
|
11
Pliant Therapeutics
PLRX
$101M
| $38.1M | 2.66% | 2,895,478 -302,013 | -9% | -$3.98M |
|
12
Beam Therapeutics
BEAM
$1.66B
| $37.9M | 2.64% | 1,528,567 -82,446 | -5% | -$2.04M |
|
13
Regenxbio
RGNX
$451M
| $37.1M | 2.58% | 4,794,780 -98,122 | -2% | -$758K |
|
14
Akero Therapeutics
AKRO
$3.74B
| $34.4M | 2.39% | 1,235,209 -152,270 | -11% | -$4.24M |
|
15
Biohaven
BHVN
$1.63B
| $33.8M | 2.35% | 904,496 -129,723 | -13% | -$4.85M |
|
16
Annexon
ANNX
$226M
| $32.3M | 2.25% | 6,300,644 -126,818 | -2% | -$651K |
|
17
ADC Therapeutics
ADCT
$345M
| $31.2M | 2.17% | 15,666,731 -2,486 | -0% | -$4.95K |
|
|
18
Neurogene
NGNE
$264M
| $30.2M | 2.1% | 1,319,763 +355,416 | +37% | +$8.12M |
|
19
Boston Scientific
BSX
$156B
| $27.9M | 1.95% | 312,683 -18,190 | -5% | -$1.62M |
|
20
Cogent Biosciences
COGT
$1.69B
| $27.7M | 1.93% | 3,554,836 -929,544 | -21% | -$7.25M |
|
21
Absci
ABSI
$357M
| $21.6M | 1.51% | 8,253,316 | – | – |
|
22
Fate Therapeutics
FATE
$120M
| $21.2M | 1.48% | 12,872,946 -296,111 | -2% | -$489K |
|
|
IGMS
23
DELISTED
IGM Biosciences
IGMS
| $18M | 1.26% | 2,952,131 -120,347 | -4% | -$735K |
|
|
24
89bio
ETNB
$1.34B
| $16.9M | 1.18% | 2,167,176 +597,326 | +38% | +$4.67M |
|
|
SLN
25
Silence Therapeutics
SLN
$227M
| $16.5M | 1.15% | 2,399,317 +500,000 | +26% | +$3.44M |
|